Search Within

Beatriz Wills Sanin

Formats
  1. Meeting Abstract (10)
  2. Journal Article (5)
  3. Review (1)
Groups
  1. Department of Medicine (16)
  2. GME, Medicine (16)
  3. Graduate Medical Education (16)
  4. Hematologic Malignancies, Division of (16)
  5. Hematology-Oncology Fellows (16)
  6. Center for Hematologic Malignancies (14)

More Groups

People
  1. Gilles Salles (10)
  2. Gunjan Shah (9)
  3. Maria Palomba (9)
  4. Heiko Schoder (7)
  5. Michael Scordo (7)
  6. Alison Moskowitz (6)

More People

Years
  1. 2024 (1)
  2. 2023 (7)
  3. 2022 (1)
  4. 2021 (5)
  5. 2020 (2)
Publications
  1. Blood (6)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. American Journal of Hematology (1)
  5. Best Practice and Research: Clinical Haematology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (1)
  5. Elsevier Inc. (1)
  6. John Wiley & Sons, Inc. (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma
    Journal Article

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Comparison of bendamustine versus fludarabine/cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy
    Meeting Abstract

    Landego, I.; Nemirovsky, D.; Devlin, S. M.; Wills, B.; Parascondola, A.; Saldia, A.; Dahi, P. B.; Tomas, A. A.; Ip, A.; Suh, H. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Occult recurrent breast cancer masquerading as thrombotic thrombocytopenic purpura
    Journal Article

    Wills-Sanin, B.; George, J. N.; Boiocchi, L.; Soff, G. A.; Mones, J. V.
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save